Kuros Biosciences AG
KURN.SWDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
I-0401 (a new bone graft substitute)
Tibia Plateau Fractures
I-020502
Burns
I-020201
Diabetic Foot Ulcer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
I-0401 (a new bone graft substitute) | Phase 2 | Tibia Plateau Fractures | - | - |
I-020502 | Phase 2 | Burns | - | - |
I-020201 | Phase 2 | Diabetic Foot Ulcer | - | - |
Frequently asked questions
What is in Kuros Biosciences AG's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Kuros Biosciences AG's (KURN.SW) pipeline across Phase 2. Its lead program is I-0401 (a new bone graft substitute) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kuros Biosciences AG's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Kuros Biosciences AG (KURN.SW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track KURN.SW biotech catalysts?→
Add KURN.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kuros Biosciences AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.